Literature DB >> 29668216

Provider and patient burdens of obtaining oral anticancer medications.

Daniel M Geynisman1, Caitlin R Meeker, Jamie L Doyle, Elizabeth A Handorf, Marijo Bilusic, Elizabeth R Plimack, Yu Ning Wong.   

Abstract

Oral anticancer medications (OAMs) are frequently used to treat patients with cancer. Unlike intravenous chemotherapy, OAMs are covered by prescription drug plans. We examined barriers to initiation of OAMs in 116 patients with prostate or kidney cancer (149 unique prescriptions). We found that the median time from initial prescription to prior authorization was 3 days and the median time from initial prescription to patient receipt of drug was 12 days. Seventy-three percent of all prescriptions required 2 or more phone calls by clinic staff and 40% required 5 or more calls. Of 107 prescriptions with data available, 54% utilized financial assistance; these required significantly more phone calls (P = .0001) and led to a longer median time to drug obtainment (P = .003) compared with those that did not require financial assistance. In those prescriptions with both initial and final co-pay information available, the initial out-of-pocket mean and median co-pays were $1226.03 and $329.73, respectively, but these dropped to $124.57 and $25.00 after utilization of co-pay assistance programs, excluding those with a $0 final co-pay. These early observations suggest that a more efficient process for initiation of OAMs is needed.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29668216

Source DB:  PubMed          Journal:  Am J Manag Care        ISSN: 1088-0224            Impact factor:   2.229


  6 in total

1.  Characterizing Out-of-Pocket Payments and Financial Assistance for Patients Prescribed Abiraterone and Enzalutamide at an Academic Cancer Center Specialty Pharmacy.

Authors:  Angelina Y Jeong; Eric B Schwartz; Andrea R Roman; Rachel L McDevitt; Mary K Oerline; Elyssa Henry; Christine M Veenstra; Megan E V Caram
Journal:  JCO Oncol Pract       Date:  2021-09-07

Review 2.  The Out-of-Pocket Cost Burden of Cancer Care-A Systematic Literature Review.

Authors:  Nicolas Iragorri; Claire de Oliveira; Natalie Fitzgerald; Beverley Essue
Journal:  Curr Oncol       Date:  2021-03-15       Impact factor: 3.677

3.  Provider- and patient-level predictors of oral anticancer agent initiation and adherence in patients with metastatic renal cell carcinoma.

Authors:  Lisa P Spees; Stephanie B Wheeler; Bradford E Jackson; Christopher D Baggett; Lauren E Wilson; Melissa A Greiner; Deborah R Kaye; Tian Zhang; Daniel George; Charles D Scales; Jessica E Pritchard; Michael Leapman; Cary P Gross; Michaela A Dinan
Journal:  Cancer Med       Date:  2021-09-04       Impact factor: 4.452

4.  Treatment Experiences with CDK4&6 Inhibitors Among Women with Metastatic Breast Cancer: A Qualitative Study.

Authors:  Judith J Stephenson; Jonathon Colby Gable; Rebekah Zincavage; Gregory L Price; Collin Churchill; Emily Zhu; Keri Stenger; Mukul Singhal; Bal Nepal; Michael Grabner; Michael J Fisch; David Debono; Amy R Geschwender; Gebra Cuyun Carter
Journal:  Patient Prefer Adherence       Date:  2021-11-03       Impact factor: 2.711

5.  Exploring healthcare providers' experiences with specialty medication and limited distribution networks.

Authors:  Megan E Peter; Autumn D Zuckerman; Elizabeth Cherry; David G Schlundt; Kemberlee Bonnet; Nisha Shah; Tara N Kelley
Journal:  PLoS One       Date:  2022-08-15       Impact factor: 3.752

6.  Changes in Burnout Among Oncology Physician Assistants Between 2015 and 2019.

Authors:  Eric D Tetzlaff; Heather M Hylton; Karen J Ruth; Zachary Hasse; Michael J Hall
Journal:  JCO Oncol Pract       Date:  2021-07-22
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.